Themes Management Co LLC Takes Position in Axon Enterprise, Inc $AXON

Themes Management Co LLC acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,212 shares of the biotechnology company’s stock, valued at approximately $1,256,000.

Several other hedge funds have also recently made changes to their positions in AXON. Evergreen Capital Management LLC increased its holdings in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the last quarter. Monte Financial Group LLC increased its holdings in Axon Enterprise by 5.5% during the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 17 shares during the last quarter. Wealth Alliance LLC increased its holdings in Axon Enterprise by 3.2% during the third quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after buying an additional 18 shares during the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in Axon Enterprise by 4.5% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 439 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 19 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in Axon Enterprise by 0.5% during the third quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock valued at $2,848,000 after buying an additional 19 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $386.00 on Tuesday. The firm has a fifty day moving average price of $414.25 and a 200-day moving average price of $499.29. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The stock has a market cap of $31.11 billion, a PE ratio of 155.02, a price-to-earnings-growth ratio of 7.02 and a beta of 1.44. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.47 earnings per share. Equities analysts anticipate that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 1,500 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares of the company’s stock, valued at $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Isaiah Fields sold 2,000 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the sale, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 13,855 shares of company stock valued at $7,109,828. Company insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Piper Sandler reduced their target price on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a report on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Needham & Company LLC reduced their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a report on Friday, February 20th. Finally, Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.